# Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)

> **NCT03345810** · PHASE2 · COMPLETED · sponsor: **AIO-Studien-gGmbH** · enrollment: 200 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Metastatic Lung Cancer
- Non Small Cell Lung Cancer
- Lung Adenocarcinoma Metastatic
- Large Cell Lung Carcinoma Metastatic

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Vinorelbine
- **DRUG:** Gemcitabine
- **DRUG:** nab-Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT03345810
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-14
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03345810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03345810, "Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03345810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*